JP2018514511A - 乳房障害とエストロゲン関連障害の処置のための組成物と方法 - Google Patents

乳房障害とエストロゲン関連障害の処置のための組成物と方法 Download PDF

Info

Publication number
JP2018514511A
JP2018514511A JP2017550122A JP2017550122A JP2018514511A JP 2018514511 A JP2018514511 A JP 2018514511A JP 2017550122 A JP2017550122 A JP 2017550122A JP 2017550122 A JP2017550122 A JP 2017550122A JP 2018514511 A JP2018514511 A JP 2018514511A
Authority
JP
Japan
Prior art keywords
breast
fatty acid
pharmaceutical composition
vitamin
omega
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017550122A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018514511A5 (cg-RX-API-DMAC7.html
Inventor
キー,スティーブン,シー.
Original Assignee
アトッサ ジェネティックス インク.
アトッサ ジェネティックス インク.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アトッサ ジェネティックス インク., アトッサ ジェネティックス インク. filed Critical アトッサ ジェネティックス インク.
Publication of JP2018514511A publication Critical patent/JP2018514511A/ja
Publication of JP2018514511A5 publication Critical patent/JP2018514511A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2017550122A 2015-04-14 2016-04-06 乳房障害とエストロゲン関連障害の処置のための組成物と方法 Pending JP2018514511A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562147536P 2015-04-14 2015-04-14
US62/147,536 2015-04-14
PCT/US2016/026170 WO2016168021A1 (en) 2015-04-14 2016-04-06 Compositions and methods of treatment of breast disorders and estrogen-related disorders

Publications (2)

Publication Number Publication Date
JP2018514511A true JP2018514511A (ja) 2018-06-07
JP2018514511A5 JP2018514511A5 (cg-RX-API-DMAC7.html) 2019-04-11

Family

ID=57127000

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017550122A Pending JP2018514511A (ja) 2015-04-14 2016-04-06 乳房障害とエストロゲン関連障害の処置のための組成物と方法

Country Status (7)

Country Link
US (1) US20180049999A1 (cg-RX-API-DMAC7.html)
EP (1) EP3283061A4 (cg-RX-API-DMAC7.html)
JP (1) JP2018514511A (cg-RX-API-DMAC7.html)
CN (1) CN107708678A (cg-RX-API-DMAC7.html)
AU (1) AU2016247674A1 (cg-RX-API-DMAC7.html)
CA (1) CA2981301A1 (cg-RX-API-DMAC7.html)
WO (1) WO2016168021A1 (cg-RX-API-DMAC7.html)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111420046A (zh) * 2020-05-27 2020-07-17 畜科生物工程有限公司 一种动物疫苗佐剂及其制备方法
JP2022507265A (ja) * 2018-11-14 2022-01-18 ユニバーシティ オブ ピッツバーグ - オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション Rad51阻害薬としての求電子剤および求電子剤プロドラッグ
JP2023518245A (ja) * 2020-03-18 2023-04-28 アール.ピー.シェーラー テクノロジーズ,エルエルシー ソフトゲルカプセル
WO2023211005A1 (ko) * 2022-04-25 2023-11-02 유엠에스엔지니어링 주식회사 오메가 3 심리스 연질캡슐 제조방법

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180169034A1 (en) * 2015-06-14 2018-06-21 Trs Ii, Llc Transdermal delivery formulation
CA2992282A1 (en) * 2015-07-14 2017-01-19 Atossa Genetics Inc. Transpapillary methods and compositions for treating breast disorders
CN110099680B (zh) 2016-10-11 2021-02-05 杜克大学 Er+乳腺癌的拉索昔芬治疗
CN111212635A (zh) * 2017-09-11 2020-05-29 阿托莎医疗公司 局部用组合物
EP3681491A4 (en) 2017-09-11 2021-06-30 Atossa Therapeutics, Inc. PROCESS FOR MANUFACTURING AND USE OF ENDOXIFES
TW201919594A (zh) * 2017-09-11 2019-06-01 美商艾陶莎基因有限公司 局部用組合物及治療方法
CA3094072A1 (en) * 2018-03-15 2019-09-19 Atossa Therapeutics, Inc. In situ methods of inducing of immune response
CN117771239A (zh) 2018-04-10 2024-03-29 杜克大学 乳腺癌的拉索昔芬治疗
WO2019232485A1 (en) * 2018-05-31 2019-12-05 Nvigen, Inc. Accurate blood test to predict cancer incidence, recurrence, guide and monitor treatment intervention
IT201900003843A1 (it) * 2019-03-15 2020-09-15 Lo Li Pharma Srl Trattamento di fibromi con vitamina D e un agente come l'epigallocatechina gallato (EGCG)
EP3980006A2 (en) * 2019-06-07 2022-04-13 Diomics Corporation Topical time release delivery using layered biopolymer
WO2021003433A1 (en) * 2019-07-03 2021-01-07 Atossa Therapeutics, Inc. Sustained release compositions of endoxifen
BR112022001165A2 (pt) * 2019-07-23 2022-05-17 Scherer Technologies Llc R P Formulações de cápsula de casca macia e métodos de preparação e uso das mesmas
US11915811B2 (en) * 2019-09-03 2024-02-27 Kaival Labs, Inc. System and method for determining an appropriate dose of a product
WO2021231904A1 (en) * 2020-05-14 2021-11-18 Diomics Corporation Detection and indication of covid-19, other viruses and pathogens and vaccine associated efficacy
WO2022187511A1 (en) * 2021-03-03 2022-09-09 Veramorph Llc Dissociating polymer matrix compositions of fulvestrant and methods of their making and use
GB202116903D0 (en) 2021-11-18 2022-01-05 Sermonix Pharmaceuticals Inc Lasofoxifene treatment of aromatase-resistant er+ cancer
WO2025174794A1 (en) * 2024-02-12 2025-08-21 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE20013336U1 (de) * 2000-08-02 2001-02-15 Bieger, Wilfried P., Priv.-Doz. Dr.med.habil., 80335 München Mund- und Zahnpflegegel

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5149851A (en) * 1990-10-25 1992-09-22 The United States Of America As Represented By The Secretary Of Commerce Process for preparing triglycerides containing polyunsaturated fatty acid moieties
US5613958A (en) * 1993-05-12 1997-03-25 Pp Holdings Inc. Transdermal delivery systems for the modulated administration of drugs
DE19738643C2 (de) * 1997-09-04 2001-10-04 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit dem Wirkstoff Scopolaminbase und Verfahren zu seiner Herstellung
WO2001001962A1 (en) * 1999-07-05 2001-01-11 Idea Ag. A method for the improvement of transport across adaptable semi-permeable barriers
NZ552316A (en) * 2006-12-22 2009-10-30 Fonterra Co Operative Group Dairy product and process
WO2008113177A1 (en) * 2007-03-20 2008-09-25 Centre De Recherche Sur Les Biotechnologies Marines Compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof and uses thereof
US20090068190A1 (en) * 2007-08-29 2009-03-12 Drugtech Corporation Anti-proliferative combinations
WO2014093313A1 (en) * 2012-12-10 2014-06-19 Jingxuan Kang Compositions and methods for integrated metabolic interventions
US8728546B1 (en) * 2013-03-15 2014-05-20 Swing Aerobics Licensing, Inc. Medicament for treatment of cancer, cardiovascular diseases and inflammation
MX370055B (es) * 2013-04-22 2019-11-29 Smartfish As Uso de una composición que comprende aceite de pescado y jugo para el tratamiento y/o postratamiento de cáncer.
CN103734512A (zh) * 2013-12-20 2014-04-23 晓健科技(大连)有限公司 一种宠物猫补钙营养膏
CA2992282A1 (en) * 2015-07-14 2017-01-19 Atossa Genetics Inc. Transpapillary methods and compositions for treating breast disorders

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE20013336U1 (de) * 2000-08-02 2001-02-15 Bieger, Wilfried P., Priv.-Doz. Dr.med.habil., 80335 München Mund- und Zahnpflegegel

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BIOCHEM. CELL BIOL., (1994), 72, [11-12], P.537-545, JPN6020001143, ISSN: 0004324229 *
CHAM. BIOL. INTERACT., (2010), 188, [1], P.102-110, JPN6020001142, ISSN: 0004324228 *
INT. J. PHARM., (2010), 387, [1-2], P.161-166, JPN6020001141, ISSN: 0004324227 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022507265A (ja) * 2018-11-14 2022-01-18 ユニバーシティ オブ ピッツバーグ - オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション Rad51阻害薬としての求電子剤および求電子剤プロドラッグ
JP7656922B2 (ja) 2018-11-14 2025-04-04 ユニバーシティ オブ ピッツバーグ - オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション Rad51阻害薬としての求電子剤および求電子剤プロドラッグ
JP2023518245A (ja) * 2020-03-18 2023-04-28 アール.ピー.シェーラー テクノロジーズ,エルエルシー ソフトゲルカプセル
JP7785682B2 (ja) 2020-03-18 2025-12-15 アール.ピー.シェーラー テクノロジーズ,エルエルシー ソフトゲルカプセル
CN111420046A (zh) * 2020-05-27 2020-07-17 畜科生物工程有限公司 一种动物疫苗佐剂及其制备方法
CN111420046B (zh) * 2020-05-27 2021-01-12 四川省畜牧科学研究院 一种动物疫苗佐剂及其制备方法
WO2023211005A1 (ko) * 2022-04-25 2023-11-02 유엠에스엔지니어링 주식회사 오메가 3 심리스 연질캡슐 제조방법

Also Published As

Publication number Publication date
CA2981301A1 (en) 2016-10-20
EP3283061A4 (en) 2019-04-17
EP3283061A1 (en) 2018-02-21
WO2016168021A1 (en) 2016-10-20
AU2016247674A1 (en) 2017-10-19
CN107708678A (zh) 2018-02-16
US20180049999A1 (en) 2018-02-22

Similar Documents

Publication Publication Date Title
CN107708678A (zh) 治疗乳房病症以及雌激素相关病症的组合物和方法
RU2275198C2 (ru) Дроспиренон для гормональной заместительной терапии
JP2026035600A (ja) 送達増強エピネフリン組成物
JP6247685B2 (ja) 実質的に水不溶性の薬物の送達のための医薬組成物
JP6938462B2 (ja) 治療用化合物の脳への一方向送達のためのインプラント組成物
CN115698013B (zh) Menin抑制剂和cyp3a4抑制剂的组合及其使用方法
CN102413821A (zh) 经皮吸收型制剂
CN111132670A (zh) 具有增强的渗透的药物组合物
JP6768682B2 (ja) メラノーマの処置に使用するためのアピリモド
CN102065900B (zh) 经皮吸收促进剂和使用其的经皮给药制剂
CN111465391A (zh) 具有增强的递送的肾上腺素和前药的组合物
JP6623084B2 (ja) S/o型貼付剤
JP2020533343A (ja) 局所用組成物
KR20060127875A (ko) 아로마타제 억제제 요법-관련된 골다공증의 치료
CN111148512A (zh) 包含渗透增强剂的递送药物组合物
JP2020533342A (ja) 局所用組成物及び処置方法
TW200901989A (en) Anti-tumor activity of CCI-779 in papillary renal cell cancer
CN116808226A (zh) 一种药物组合物及其制备方法和应用、含其的埋植剂
TW201202232A (en) Treatment of GIST with masitinib
JP2005528432A (ja) ノルエチンドロン徐放処方物およびそれに関連する方法
Novorý et al. Tamoxifen in cancer therapy
HRP20020666A2 (en) Drospirenone for hormone replacement therapy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171002

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171121

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171010

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190228

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190304

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200120

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200817